Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell^®

The vast majority of SARS-CoV-2 vaccines which are licensed or under development focus on the spike (S) protein and its receptor binding domain (RBD). However, the S protein shows considerable sequence variations among variants of concern. The aim of this study was to develop and characterize a SARS...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sevastyan O. Rabdano, Ellina A. Ruzanova, Iuliia V. Pletyukhina, Nikita S. Saveliev, Kirill L. Kryshen, Anastasiia E. Katelnikova, Petr P. Beltyukov, Liliya N. Fakhretdinova, Ariana S. Safi, German O. Rudakov, Sergei A. Arakelov, Igor V. Andreev, Ilya A. Kofiadi, Musa R. Khaitov, Rudolf Valenta, Daria S. Kryuchko, Igor A. Berzin, Natalia S. Belozerova, Anatoly E. Evtushenko, Viktor P. Truhin, Veronika I. Skvortsova
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2023-04-01
Serie:	Vaccines
Soggetti:	protein N nucleocapsid vaccine SARS-CoV-2 COVID-19
Accesso online:	https://www.mdpi.com/2076-393X/11/4/874
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!